类风湿关节炎相关间质性肺病成人患者的生存率——系统综述与Meta分析
该系统综述与Meta分析纳入78项研究,评估类风湿关节炎相关间质性肺病(RA-ILD)患者自诊断起的生存时长。汇总累计死亡率在1年内为9.0%,>1至≤3年为21.4%,>3至≤5年为30.2%,>5至≤10年为49.1%,异质性高,仅15项研究在4个领域均为低偏倚风险。
要点
- RA-ILD患者自诊断起中位生存期为2至14年,汇总累计死亡率随年限增加而升高。
- 汇总累计死亡率:≤1年9.0%,>1至≤3年21.4%,>3至≤5年30.2%,>5至≤10年49.1%。
- 仅15项研究在4个领域均为低偏倚风险,异质性高限制结论强度,需进一步研究自然史。
核心结论
- 本综述总结了RA-ILD的高死亡率,但结论强度受限于现有研究因方法学和临床因素导致的高异质性。
- 需要进一步研究以更好地了解该病的自然史。
研究设计与样本
- 系统综述与Meta分析,检索Medline(Ovid)、Embase(OVID)、CINAHL(EBSCO)、PubMed和Cochrane Library,纳入报告自RA-ILD诊断起生存时长的研究,共纳入78项研究。
- 采用预后研究质量工具(Quality In Prognosis Studies)的4个领域评估纳入研究的偏倚风险。
主要发现
- 总RA-ILD人群的中位生存期为2至14年。
- 汇总累计死亡率:≤1年9.0%(95%CI 6.1, 12.5,I²=88.9%),>1至≤3年21.4%(95%CI 17.3, 25.9,I²=85.7%),>3至≤5年30.2%(95%CI 24.8, 35.9,I²=87.7%),>5至≤10年49.1%(95%CI 40.6, 57.7,I²=85.0%)。
- 异质性高;仅15项研究在评估的全部4个领域被评为低偏倚风险。
关键数值与推荐
- 累计死亡率按≤1年、>1至≤3年、>3至≤5年、>5至≤10年四个时间段进行Meta分析,分别针对总RA-ILD人群和按ILD模式分组。
- 中位生存期结果以表格呈现并进行定性讨论。
临床怎么用
- 原文未据此给出推荐。
局限性
- 结论强度受限于现有研究因方法学和临床因素导致的高异质性。
- 仅15项研究在评估的全部4个领域被评为低偏倚风险。
- 需要进一步研究以更好地了解该病的自然史。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is associated with high levels of morbidity and mortality. The primary aim of this systematic review was to determine the duration of survival, from time of diagnosis of RA-ILD. METHODS: Medline (Ovid), Embase (OVID), CINAHL (EBSCO), PubMed, and the Cochrane Library were searched for studies that reported duration of survival from time of diagnosis of RA-ILD. Risk of bias of included studies was assessed based upon 4 domains of the Quality In Prognosis Studies tool. Results for median survival were presented by tabulation and discussed qualitatively. Meta-analysis of cumulative mortality at 1 year, >1y to ≤3 years, >3 years to ≤5 years, and >5 years to≤ 10 years was undertaken, for total RA-ILD population, and according to ILD pattern. RESULTS: 78 studies were included. Median survival for the total RA-ILD population ranged from 2 to 14 years. Pooled estimates for cumulative percentage mortality up to 1 year were 9.0% (95% CI 6.1, 12.5, I2 88.9%), >1 to ≤3 years 21.4% (17.3, 25.9, I2 85.7%), >3 to ≤ 5 years 30.2% (24.8, 35.9, I2 87.7%), and > 5 to ≤ 10 years 49.1% (40.6, 57.7 I2 85.0%). Heterogeneity was high. Only 15 studies were rated as low risk of bias in all 4 domains assessed. CONCLUSION: This review summarises the high mortality of RA-ILD, however the strength of conclusions that can be made is limited by the heterogeneity of the available studies, due to methodological and clinical factors. Further studies are needed to better understand the natural history of this condition.
引用
- Farquhar HJ, Beckert N, Beckert L, et al. Survival of adults with rheumatoid arthritis associated interstitial lung disease - A systematic review and meta-analysis. Semin Arthritis Rheum. 2023. PMID: 36933302. doi:10.1016/j.semarthrit.2023.152187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。